Credit Suisse’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.44M | Hold |
33,365
| – | – | ﹤0.01% | 1724 |
|
|
2023
Q4 | $2.38M | Buy |
33,365
+852
| +3% | +$50.3K | ﹤0.01% | 1782 |
|
|
2023
Q3 | $1.95M | Buy |
32,513
+1,936
| +6% | +$127K | ﹤0.01% | 1858 |
|
|
2023
Q2 | $2.2M | Buy |
30,577
+5,766
| +23% | +$433K | ﹤0.01% | 1843 |
|
|
2023
Q1 | $1.83M | Buy |
24,811
+1,310
| +6% | +$93.1K | ﹤0.01% | 1938 |
|
|
2022
Q4 | $1.57M | Sell |
23,501
-11,957
| -34% | -$777K | ﹤0.01% | 2022 |
|
|
2022
Q3 | $1.91M | Sell |
35,458
-100
| -0.3% | -$5.88K | ﹤0.01% | 1888 |
|
|
2022
Q2 | $1.98M | Sell |
35,558
-1,943
| -5% | -$110K | ﹤0.01% | 1925 |
|
|
2022
Q1 | $2.63M | Buy |
37,501
+978
| +3% | +$71K | ﹤0.01% | 1896 |
|
|
2021
Q4 | $3.52M | Sell |
36,523
-3,781
| -9% | -$349K | ﹤0.01% | 2315 |
|
|
2021
Q3 | $3.5M | Buy |
40,304
+1,204
| +3% | +$93.1K | ﹤0.01% | 2347 |
|
|
2021
Q2 | $3.2M | Sell |
39,100
-3,585
| -8% | -$298K | ﹤0.01% | 2470 |
|
|
2021
Q1 | $4.06M | Sell |
42,685
-38,079
| -47% | -$3.6M | ﹤0.01% | 2248 |
|
|
2020
Q4 | $5.01M | Buy |
80,764
+15,051
| +23% | +$858K | ﹤0.01% | 2088 |
|
|
2020
Q3 | $3.91M | Sell |
65,713
-10,773
| -14% | -$735K | ﹤0.01% | 1953 |
|
|
2020
Q2 | $5.34M | Sell |
76,486
-36,394
| -32% | -$2.31M | ﹤0.01% | 1668 |
|
|
2020
Q1 | $5.12M | Buy |
112,880
+34,602
| +44% | +$1.96M | ﹤0.01% | 1534 |
|
|
2019
Q4 | $5.09M | Buy |
78,278
+34,003
| +77% | +$2.27M | ﹤0.01% | 1864 |
|
|
2019
Q3 | $2.75M | Sell |
44,275
-28,729
| -39% | -$1.8M | ﹤0.01% | 2234 |
|
|
2019
Q2 | $5.2M | Buy |
73,004
+16,428
| +29% | +$1.21M | ﹤0.01% | 1733 |
|
|
2019
Q1 | $4.44M | Sell |
56,576
-7,049
| -11% | -$534K | ﹤0.01% | 1800 |
|
|
2018
Q4 | $5.39M | Buy |
63,625
+7,922
| +14% | +$845K | 0.01% | 1523 |
|
|
2018
Q3 | $9.54M | Sell |
55,703
-5,344
| -9% | -$806K | 0.01% | 1284 |
|
|
2018
Q2 | $7.89M | Buy |
61,047
+2,698
| +5% | +$301K | 0.01% | 1391 |
|
|
2018
Q1 | $6.01M | Sell |
58,349
-1,395
| -2% | -$138K | 0.01% | 1586 |
|
|
2017
Q4 | $5.1M | Sell |
59,744
-15,450
| -21% | -$1.34M | ﹤0.01% | 1769 |
|
|
2017
Q3 | $6.39M | Sell |
75,194
-97,465
| -56% | -$7.72M | 0.01% | 1576 |
|
|
2017
Q2 | $13.1M | Sell |
172,659
-30,970
| -15% | -$2.17M | 0.01% | 1040 |
|
|
2017
Q1 | $13.4M | Buy |
203,629
+51,958
| +34% | +$3.42M | 0.01% | 1050 |
|
|
2016
Q4 | $9.61M | Buy |
151,671
+31,557
| +26% | +$1.99M | 0.01% | 1226 |
|
|
2016
Q3 | $7.65M | Sell |
120,114
-16,147
| -12% | -$1.19M | 0.01% | 1359 |
|
|
2016
Q2 | $10.1M | Sell |
136,261
-16,364
| -11% | -$1.21M | 0.01% | 1152 |
|
|
2016
Q1 | $10.2M | Buy |
152,625
+17,468
| +13% | +$1.06M | 0.01% | 1106 |
|
|
2015
Q4 | $9.14M | Sell |
135,157
-40,638
| -23% | -$2.51M | 0.01% | 1200 |
|
|
2015
Q3 | $9.39M | Sell |
175,795
-41,472
| -19% | -$2.52M | 0.01% | 1155 |
|
|
2015
Q2 | $13.7M | Buy |
217,267
+69,874
| +47% | +$3.81M | 0.01% | 1042 |
|
|
2015
Q1 | $7.09M | Buy |
147,393
+6,023
| +4% | +$231K | 0.01% | 1418 |
|
|
2014
Q4 | $4.69M | Sell |
141,370
-6,048
| -4% | -$197K | ﹤0.01% | 1811 |
|
|
2014
Q3 | $4.32M | Sell |
147,418
-53,690
| -27% | -$1.78M | ﹤0.01% | 1866 |
|
|
2014
Q2 | $7.82M | Buy |
201,108
+40,875
| +26% | +$1.66M | 0.01% | 1584 |
|
|
2014
Q1 | $6.72M | Sell |
160,233
-8,401
| -5% | -$350K | 0.01% | 1528 |
|
|
2013
Q4 | $5.53M | Buy |
168,634
+79,627
| +89% | +$2.59M | 0.01% | 1757 |
|
|
2013
Q3 | $2.4M | Buy |
89,007
+33,428
| +60% | +$940K | ﹤0.01% | 2239 |
|
|
2013
Q2 | $1.3M | Buy |
+55,579
| New | +$1,000K | ﹤0.01% | 2600 |
|
Other funds holding LGND
SIMG
CCMLC
SDJVC
Credit Suisse's LGND Position: Q1 2024 in Review
Credit Suisse held its Ligand Pharmaceuticals (LGND) position steady in Q1 2024 at 33,365 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1724.
Credit Suisse first reported a position in LGND in Q2 2013 and has held it in 44 quarters since. The position peaked at $13.7M in Q2 2015. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.
- Credit Suisse held 33,365 shares of Ligand Pharmaceuticals worth $2.44M as of Q1 2024.
- Credit Suisse left its Ligand Pharmaceuticals share count unchanged in Q1 2024.
- Ligand Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1724 holding.
- Credit Suisse first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Ligand Pharmaceuticals position peaked at $13.7M in Q2 2015.
- 222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.